BonoFill-II

Phase 2Biologic

BBonusBio Group Ltd

BonoFill-II is one of 2 biologic programs targeting Bone Regeneration. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone RegenerationRecruiting

Bone RegenerationPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Bone Regeneration

#DrugCompanyPhaseTrials

Zocor

OOrganon and Co

Phase 1

1 2

BonoFill-II

BBonusBio Group Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Bone Regeneration

NCT03024008

Clinical

Trials by Indication[1]

Bone Regeneration2 trials

Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Recruiting·BBonusBio Group Ltd·Phase 1/2·NCT03024008·40 enrolled

Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration

Completed·BBonusBio Group Ltd·Phase 1/2·NCT02842619·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BonoFill-II. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BonoFill-II compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BonoFill-II. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BonusBio Group Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBonusBio Group Ltd

BonoFill-II

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Bone Regeneration2 trials

References

Drug Info

Quick Facts

Related News